학술논문
Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies.
Document Type
Editorial
Author
Source
Subject
*RADIATION injuries
*GRAVES' disease
*IODINE isotopes
*ACUTE myeloid leukemia
*CAT diseases
*
*
*
*
Language
ISSN
1619-7070
Abstract
For nearly eight decades [[1]] now, radioactive iodine (RAI) therapy has been playing an important role in the treatment of benign thyroid diseases (BTD) as well as differentiated thyroid cancer (DTC) [[2]]. Unfortunately, as illustrated in a previous review [[6]], thus far, no studies proving a relationship between I-131 therapy and an elevated malignancy risk fulfilling all these methodological criteria are available for I-131 therapy of benign thyroid disease. A few weeks ago, a paper exploring the relationship between I-131 therapy of benign thyroid disease and the incidence of malignancies after this therapy was published [[9]]. 6 Verburg FA, Luster M, Lassmann M, Reiners C. (131) I therapy in patients with benign thyroid disease does not conclusively lead to a higher risk of subsequent malignancies. [Extracted from the article]